USNA USANA HEALTH SCIENCES INC
Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 896264 · Fiscal year ends 01/03
Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.8%
TTM net income YoY-224.8%
TTM EPS YoY-226.7%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR—
Margins
Gross margin77.3%
Operating margin-0.4%
Net margin-2.3%
FCF margin3.3%
EBITDA margin3.2%
Returns
ROE-4.0%
ROA-3.0%
ROIC (approx.)-0.8%
Asset turnover1.26x
Leverage & solvency
Liabilities / assets19.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-9.35x
Cash quality & payout
Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-10-03 | 2026Q22026-07-04 | 2026Q12026-04-04 | 2025Q4*2026-01-03 | 2025Q32025-09-27 | 2025Q22025-06-28 | 2025Q12025-03-29 | 2023Q4*2024-12-28 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $205.88M | $223.27M | $250.22M | $226.20M | $213.67M | $235.85M | $249.54M | $213.61M |
| Cost of revenue | $48.72M | $48.34M | $59.44M | $49.41M | $48.81M | $50.18M | $52.45M | $38.55M |
| Gross profit | $157.17M | $174.93M | $190.78M | $176.79M | $164.85M | $185.66M | $197.09M | $175.06M |
| SG&A expense | $86.73M | $82.32M | $88.25M | $78.08M | $85.95M | $81.91M | $91.44M | $73.35M |
| Operating income | -$1.45M | -$20.00M | $13.87M | $3.82M | $1.22M | $16.72M | $15.67M | $8.21M |
| Interest expense | $38,000 | $0 | $240,000 | $123,000 | $49,000 | $259,000 | $411,000 | $129,000 |
| Pretax income | -$804,000 | -$18.90M | $15.46M | $4.18M | $1.79M | $18.82M | $16.74M | $10.43M |
| Income tax | $6.09M | $9.05M | $8.51M | $5.77M | $8.46M | $8.37M | $7.45M | $5.95M |
| Net income | -$5.56M | -$21.38M | $7.51M | -$1.77M | -$6.52M | $9.65M | $9.40M | $4.45M |
| EBITDA | $6.67M | -$12.32M | $22.15M | $12.38M | $9.14M | $24.46M | $24.01M | $12.21M |
| EPS (basic) | -0.30 | -1.16 | 0.41 | — | -0.36 | 0.52 | 0.49 | — |
| EPS (diluted) | -0.30 | -1.16 | 0.41 | — | -0.36 | 0.52 | 0.49 | — |
| Weighted avg. shares (diluted) | 18.50M | 18.49M | 18.41M | — | 18.29M | 18.54M | 19.09M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $178.91M | $168.56M | $162.75M | $158.38M | $145.35M | $151.34M | $179.61M | $181.77M |
| Receivables | $5.03M | $3.34M | $9.66M | $4.29M | — | — | — | — |
| Inventory | $84.08M | $86.34M | $96.36M | $102.61M | $90.78M | $83.27M | $73.56M | $69.73M |
| Current assets | $290.24M | $281.07M | $294.23M | $288.40M | $264.06M | $261.87M | $281.39M | $279.19M |
| PP&E, net | $94.60M | $94.27M | $94.62M | $94.38M | $96.21M | $96.53M | $94.25M | $94.56M |
| Goodwill | $109.26M | $109.14M | $138.13M | $137.96M | $144.29M | $144.23M | $144.22M | $144.17M |
| Intangibles | $120.41M | $124.61M | $128.90M | $133.15M | $138.16M | $142.75M | $147.16M | $151.82M |
| Total assets | $708.47M | $703.21M | $738.97M | $742.91M | $726.59M | $734.53M | $746.60M | $748.19M |
| Current liabilities | $112.25M | $105.67M | $117.24M | $128.56M | $118.66M | $121.62M | $137.38M | $139.62M |
| Total liabilities | $138.38M | $132.24M | $144.18M | $156.64M | $145.04M | $148.97M | $162.72M | $161.86M |
| Shareholders' equity | $526.76M | $526.31M | $543.55M | $533.10M | $528.07M | $531.06M | $529.76M | $532.11M |
| Shares outstanding | 18.48M | 18.46M | 18.46M | 18.28M | 18.27M | 18.26M | 18.79M | 19.06M |
| Cash flow statement | ||||||||
| Operating cash flow | $11.96M | $23.32M | $9.76M | -$3.39M | -$1.96M | $12.22M | $15.48M | $5.79M |
| Capital expenditure | $3.52M | $3.15M | $2.65M | $2.79M | $3.20M | $5.03M | $2.80M | $1.80M |
| Free cash flow | $8.44M | $20.16M | $7.11M | -$6.18M | -$5.16M | $7.19M | $12.68M | $3.98M |
| Investing cash flow | -$3.52M | -$4.06M | -$2.60M | $1.11M | -$3.20M | -$4.16M | -$3.88M | -$205.14M |
| Financing cash flow | -$92,000 | -$14.03M | -$3.64M | $13.45M | -$979,000 | -$38.61M | -$14.47M | $22.93M |
| Depreciation & amortization | $8.12M | $7.67M | $8.28M | $8.56M | $7.92M | $7.74M | $8.34M | $4.00M |
| Stock-based compensation | $3.40M | $3.40M | $3.45M | $3.75M | $3.58M | $3.62M | $2.88M | $3.61M |
| Share buybacks | $0 | $0 | $0 | $0 | $0 | $15.21M | $12.30M | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.